Vtv Therapeutics (VTVT) said Monday that the US Food and Drug Administration has lifted a clinical hold on its cadisegliatin clinical program, including a phase 3 trial in type 1 diabetes.
The company said it plans to resume the trial after submitting a protocol amendment to reduce its duration from 12 months to 6 months, accelerating the initiation of more extensive pivotal studies for a future marketing submission.
The primary endpoint of assessing certain hypoglycemia rates at 6 months will remain unchanged, Vtv Therapeutics said.
The biopharmaceutical company said the FDA imposed a clinical hold last July due to an unresolved chromatographic signal in a study, and that the hold was lifted after it submitted a response confirming the signal was an experimental artifact.
Shares were over 13% higher in recent premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。